• Nasdaq flagged Skye Bioscience for failing to meet the $2.5 million minimum stockholders’ equity requirement under Listing Rule 5550(b)(1).
• Stockholders’ equity was ($497,307) in its Form 10-Q for the quarter ended June 30, 2026.
• Shares continue trading on Nasdaq under “SKYE” with no immediate impact.
• Skye must submit a compliance plan by Oct. 2, 2026; Nasdaq could extend the cure period to Feb. 14, 2027.
• Failure to regain compliance could trigger delisting proceedings, with an appeal option that would keep the stock listed during review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-057804), on August 19, 2026, and is solely responsible for the information contained therein.